EA201000617A1 - Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей - Google Patents

Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей

Info

Publication number
EA201000617A1
EA201000617A1 EA201000617A EA201000617A EA201000617A1 EA 201000617 A1 EA201000617 A1 EA 201000617A1 EA 201000617 A EA201000617 A EA 201000617A EA 201000617 A EA201000617 A EA 201000617A EA 201000617 A1 EA201000617 A1 EA 201000617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inflammatory
antagonist
treatment
inhibitor
purin
Prior art date
Application number
EA201000617A
Other languages
English (en)
Inventor
Робин Алек Фэрхёрст
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201000617A1 publication Critical patent/EA201000617A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описано лекарственное средство, включающее по отдельности или совместно компонент (А), который представляет собой агонист аденозинового рецептора А, определенный в описании; и компонент (В), который представляет собой одно или большее количество соединений, выбранных из группы, включающей: (i) кортикостероид, (ii) агонист бета-2 адренорецептора, (iii) антимускариновое средство, (iv) антагонист A, (v) антигистамин, (vi) ингибитор каспазы, (vii) ингибитор ENaC, (viii) антагонист LTB4, (ix) антагонист LTD4, (х) ингибитор серинпротеазы, (xi) ингибитор PDE4 и (xii) двойной агонист бета-2 адренорецептора/мускариновый антагонист, предназначенное для одновременного, последовательного или раздельного введения при лечении воспалительного или обструктивного заболевания дыхательных путей.
EA201000617A 2007-10-17 2008-10-15 Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей EA201000617A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118721 2007-10-17
PCT/EP2008/063869 WO2009050198A2 (en) 2007-10-17 2008-10-15 Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases

Publications (1)

Publication Number Publication Date
EA201000617A1 true EA201000617A1 (ru) 2010-10-29

Family

ID=39185790

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000617A EA201000617A1 (ru) 2007-10-17 2008-10-15 Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей

Country Status (21)

Country Link
US (1) US20090181934A1 (ru)
EP (1) EP2211865A2 (ru)
JP (1) JP2011500630A (ru)
KR (1) KR20100075925A (ru)
CN (1) CN101827596A (ru)
AR (1) AR068879A1 (ru)
AU (1) AU2008313788A1 (ru)
BR (1) BRPI0818005A2 (ru)
CA (1) CA2702942A1 (ru)
CL (1) CL2008003057A1 (ru)
CR (1) CR11341A (ru)
CU (1) CU20100065A7 (ru)
EA (1) EA201000617A1 (ru)
IL (1) IL204723A0 (ru)
MA (1) MA31796B1 (ru)
MX (1) MX2010004252A (ru)
PE (1) PE20091392A1 (ru)
TN (1) TN2010000168A1 (ru)
TW (1) TW200927129A (ru)
WO (1) WO2009050198A2 (ru)
ZA (1) ZA201002336B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
KR20100068286A (ko) * 2007-10-17 2010-06-22 노파르티스 아게 아데노신 ａ1 수용체 리간드로서의 퓨린 유도체
JP6042968B2 (ja) 2012-04-20 2016-12-14 ユセベ ファルマ ソシエテ アノニム パーキンソン病の処置方法
JP2022517978A (ja) 2019-01-11 2022-03-11 オメロス コーポレーション がんを処置するための方法および組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
PL2322525T3 (pl) * 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MA31796B1 (fr) 2010-10-01
AR068879A1 (es) 2009-12-09
CA2702942A1 (en) 2009-04-23
TW200927129A (en) 2009-07-01
CL2008003057A1 (es) 2009-06-26
US20090181934A1 (en) 2009-07-16
IL204723A0 (en) 2010-11-30
WO2009050198A2 (en) 2009-04-23
ZA201002336B (en) 2011-04-28
CU20100065A7 (es) 2011-10-05
MX2010004252A (es) 2010-04-30
AU2008313788A1 (en) 2009-04-23
CN101827596A (zh) 2010-09-08
EP2211865A2 (en) 2010-08-04
TN2010000168A1 (en) 2011-11-11
WO2009050198A3 (en) 2009-09-11
BRPI0818005A2 (pt) 2015-04-14
KR20100075925A (ko) 2010-07-05
PE20091392A1 (es) 2009-10-14
JP2011500630A (ja) 2011-01-06
CR11341A (es) 2010-05-06

Similar Documents

Publication Publication Date Title
EA201000617A1 (ru) Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
BRPI0617673C1 (pt) composições de inibidores de fosfodiesterase do tipo iv
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
TW200602022A (en) Use of PDE III inhibitor for the reduction of heart size in mammals suffering from heart failure
EP2210606A3 (en) Compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
MA29799B1 (fr) Administration d&#39;inhibiteurs de dipeptidyl peptidase
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
JP2008528469A5 (ru)
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2007126964A3 (en) Kinase inhibitors
NO20065483L (no) Kombinasjoner omfattende antimuskarinmidler og PDE4-inhibitorer
SI2529622T1 (en) Bruton tyrosine kinase inhibitors
TW200735874A (en) Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
RS74403A (en) Derivatives of n-(arylslfonyl)beta- aminoacids comprising a supstituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
WO2009045309A3 (en) Use of v2 receptor antagonists in combination with vasopressinergic agonists
RU2011111117A (ru) Лечение аутоиммунных заболеваний
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
WO2006124996A3 (en) Inhibitors of polo-like kinase-1
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl